Current Therapy in Autoimmune Bullous Diseases by Svecova, Danka
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Current Therapy in Autoimmune Bullous Diseases
Danka Svecova
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.71541
Abstract
The goal of the treatment of autoimmune bullous disease is to reduce the production of
pathogenic autoantibodies or increase elimination of pathogenic autoantibodies from
serum of the patients. Immunosuppressive therapy reduces the production of autoanti-
bodies. The therapy protocol is divided into three phases. The first is a control phase
with the highest dose of immunosuppressive drugs suppressing activity of disease,
followed with a consolidation phase, when the bulk of lesions is healed. The last phase
is a maintenance phase when immunosuppressive medication is gradually tapered to
the lowest level that suppresses the appearance of new lesions. In complete remission off
therapy, the patient reached complete clinical remission and does not use any immuno-
suppressive medication. In complete remission on therapy, the patient uses a minimal
immunosuppressive therapy. The first-line treatment is corticosteroids in pemphigus
and pemphigoid groups. Adjuvant immunosuppressive drugs are combined with sys-
temic corticosteroids and display a corticosteroid sparing effect. First-line immunosup-
pressive adjuvants comprise azathioprine, mycophenolate mofetil and mycophenolic
acid. Rituximab, intravenous immunoglobulin G, immunoadsorption, cyclophospha-
mide, dapsone, and methotrexate are regarded as the second-line adjuvants. In derma-
titis herpetiformis, a gluten free diet eliminates the clinical symptoms. Dapsone is
regarded to be a valid therapeutic option in management of dermatitis herpetiformis.
Keywords: immunosuppressive therapy, corticosteroids, azathioprine, mycophenolate
mofetil, cyclophosphamide, methotrexate, dapsone, rituximab, intravenous
immunoglobulin G, immunoadsorption, tetracycline, gluten free diet
1. Introduction
Autoimmune bullous diseases belong to disorders that have low incidence but a high morbidity
and mortality. Rupturing of blisters leads to painful erosions that cause significant loss of body
fluid, electrolytes and proteins, especially in cases with extensive body surface involvement. If
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mucous membrane of the mouth, pharynx and esophagus are involved, the patient may not be
able to tolerate adequate intake of food and medication. Erosions on the skin and mucosa can
lead to secondary infections which may cause life-threatening events such as sepsis and cardiac
failure. Autoimmune bullous diseases warrant the use of high dose of systemic corticosteroids
and immunosuppressive drugs that may be associated with various adverse and other side
effects. Moreover, considerable risk for serious systemic complications should be predicted.
Pemphigus vulgaris is a rare autoimmune bullous disease, but one of the most severe with the
highest morbidity and mortality rates, and one requiring the highest doses of corticosteroids and
adjuvant agents. Before the advent of systemic corticosteroids, the prognosis of pemphigus
vulgaris was fatal within 2 years from diagnosis. The introduction of corticosteroids in the
1950s dramatically reduced mortality rates from around 70 to 30%. The use of adjuvant immu-
nosuppressive agent in management of autoimmune bullous diseases in the 1960s decreases
mortality rates to 10% [1]. Nowadays, it is estimated that mortality rates of pemphigus is in the
range of 5–10% [2]. Among autoimmune bullous disease, the most frequent disorder is bullous
pemphigoid. The mortality rate of bullous pemphigoid is age dependent and ranges in 2.43–
9.5% [3]. A higher mortality is influenced by old age, widespread disease, high dose of oral
corticosteroids and life-threatening comorbidities. Bullous pemphigoid has shown increasing
incidence rates in recent decades, especially in Western societies. However, bullous pemphigoid
rarely represents a life-threatening disease. In bullous pemphigoid, the risk factors that can
evoke disease should be identified and eradicated. A provoking drug or underlying malignancy
is the most frequent risk factors in bullous pemphigoid. In therapy management, many immu-
nosuppressive drugs are contraindicated because of comorbidities or malignancy in the history.
The therapy modalities used to treat autoimmune bullous disease have different mechanisms
affecting the pathophysiology of the disease. Some medications yield in suppression produc-
tion of the pathogenic autoantibodies and some have anti-inflammatory activity. Immunosup-
pressive activity is used in the corticosteroids, azathioprine, mycophenolate mofetil,
cyclophosphamide, methotrexate, and others. Medication with anti-inflammatory activity is
aimed at suppressing the inflammatory process. The last group includes topical corticoste-
roids, dapsone and sulfonamides, as well as anti-inflammatory antibiotics. Immunoadsorption
is another modality using the removal of the pathogenic autoantibodies and inflammatory
mediators. A new biologic therapy is intravenous immunoglobulin G and rituximab, mono-
clonal antibody to transmembrane protein CD20 of B-cells. In general, immunosuppressive
and anti-inflammatory medications are commonly utilized in various autoimmune bullous
diseases. Dermatitis herpetiformis is one of the diseases with specific treatment regimen,
namely a gluten free diet that may improve gluten reverses of underlying gluten-sensitive
enteropathy and so the results in remission of the skin disease.
2. Management of autoimmune bullous diseases
Management of autoimmune bullous disease should start with initial evaluation of the disease
and the patient’s condition in order to evaluate the risk of complications developing from
immunosuppressive therapy. The clinical diagnosis should be confirmed with the histopathol-
ogy of the blister, direct immunofluorescence microscopy (DIF) of the perilesional skin,
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serological detection of autoantibodies by indirect immunofluorescence microscopy (IIF),
enzyme-linked immunosorbent assay (ELISA), or immunoblot or immunoprecipitation.
The work-up before corticosteroid or immunosuppressive therapy should account for: a com-
plete blood count, creatinine, urea, blood electrolytes, transaminases, gamma GT, alkaline phos-
phatase, total serum protein, albumin, glucose, hepatitis B, C and HIV, and chest X-ray. Optional
examination predicting used medication includes analysis of thiopurine methyltransferase
(TPMT) activity when azathioprine is considered; glucose-6-phosphate dehydrogenase (G6PD)
serum activity, bilirubin, and reticulocytes if dapsone is recommended; and serum IgA defi-
ciency should be ruled out prior to intravenous immunoglobulin therapy. Abdominal sonogra-
phy is optional. QuantiFERONE or PPD is recommended where there is a risk of tuberculosis; a
βhuman chorionic gonadotropin (βHCG) blood test is used to exclude pregnancy in women of
childbearing age; osteodensitometry is recommended prior to corticosteroid therapy and period-
ically evaluated during the regimen; ophthalmological examination is performed prior to corti-
costeroid therapy and periodically repeated to exclude glaucoma and cataract.
A general examination should asses the patient’s general condition including bodyweight,
arterial blood pressure, and comorbidities such as cardiovascular, musculoskeletal or neoplas-
tic, diabetes, etc.
Laboratory monitoring of pathogenic autoantibodies should be performed in autoimmune
bullous diseases to predict outcome of the disease as well as to evaluate the efficacy of the
employed therapy regimen.
In pemphigus patients, detection of pathogenic IgG antibodies by ELISA is positive in 90% of
patients and correlates with disease activity. A quantitative evaluation of anti-Dsg3 and anti-
Dsg1 IgG is evaluated using ELISA or IIF. Both methods can predict activity or curability of
disorder. Determination of serum antibodies is performed on initiation of therapy, after
3 months and every 3–6 months based on disease activity and relapse [4]. Immunoblot and
immunoprecipitation can also be used. In paraneoplastic pemphigus, the autoantibody to
various antigens can be detected, including envoplakin, periplakin, desmocollin, desmoplakin,
desmogleins, BP180 antigen, BP230 antigen, and plectin.
In patients with bullous pemphigoid, pathogenic anti-BP180 IgG autoantibodies are evaluated
by ELISA or IIF. A quantitative evaluation should be monitored at days 0, 60, and 150 during
treatment. A negative anti-BP180 IgG antibody at day 150 has a good predictive value of
durable remission in approximately 90% [5].
In patients with dermatitis herpetiformis, pathogenic autoantibodies are IgA against tissue
transglutaminase (anti-tTG) and IgA against endomysia (primate smooth muscle reticular
connective tissue, EMA). Tissue transglutaminase (tTG) antigens share a 64% homology with
epidermal transglutaminase, which is the target antigen in dermatitis herpetiformis. Detection
by ELISA anti-tTG IgA is positive in 90% of patients with dermatitis herpetiformis. Detection
of EMA IgA antibody uses IIF and is positive in 100% of patients with dermatitis herpetiformis
[6]. Both markers are useful in detection of bowel damage and gluten-free diet compliance in
patients with dermatitis herpetiformis and they disappear, if a gluten-free diet is strictly
adherent. In general, monitoring of autoantibodies reflect patient’s adherence to a gluten-free
diet. Serological evaluation is sensitive to detecting major but not minor failure in diet.
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Therapy protocol of pemphigus group diseases and pemphigoid diseases is divided into three
phases, based on the activity of the disease. The first is the induction phase, followed by a
consolidation phase and then a maintenance phase. During the induction phase, control of
disease should be established usually by a high dose of immunosuppressant agent, mostly
corticosteroids. Bullous disease usually responds to treatment within 2 weeks, provided the
correct dose is used. In the consolidation phase, the dropped dose of medication is used until the
bulk of lesions have been healed. Slow healing is an indicator that the dose of medication is
inadequate and should be boosted. The maintenance phase begins once most lesions have been
healed (80%). The rate of medication tapering is based on clinical improvement of the disease and
the physician’s experience. If new lesions (one to five) appear while medication is tapering, these
can be treated with high potency topical or intralesional corticosteroid, while maintaining
patients on their current dose of systemic medications. If many new lesions appear, the dose of
corticosteroids should be increased in 25–50% increments until control of disease is achieved. In
most patients, the healing is slow, often requiring a period of 1–3 months for complete clearance
of lesions. Discontinuation of immunosuppressive therapy may be proposed if complete remis-
sion is achieved with a low dose of systemic corticosteroid (prednisolone ≤10 mg/day) for a
period of 6–12 months. Remission should be supported by negative DIF data. DIF data is a
sensitive method for autoantibody detection in tissue in active disease, as well as in remission.
Furthermore, DIF data correlate with the immunological activity of the disease. Patients with a
higher autoantibody titer and positive DIF data are likely to experience disease relapse. In
pemphigus group, the titer of autoantibodies correlates with disease activity, while not so closely
in the bullous pemphigoid group, but also is used in monitoring.
The aim of treatment is to suppress disease activity with the minimum dose of drug necessary to
induce complete remission, with minimum dose resulting in minimum adverse events, allowing
all therapies to be discontinued. Duration of different treatment regimens is not standardized,
ranging from 1 to 5 years or even longer. Long-term treatment leads to a high accumulation of
corticosteroids and adjuvant drugs, leading to the development of adverse events from all used
medications. In general, minimizing potential adverse effects of corticosteroids could be man-
aged by agent that reduces osteoporosis and antacids, following a diet low in sugar and salt. In
methotrexate protocol, the bone marrow depression could be reduced with folic acid. It is also
important to reduce risk factors such as bacterial or viral infections, sun exposure and radiation
therapy, large dental procedure, and psychical stress. In dermatitis herpetiformis, the most
preferred precaution is to avoid a diet failure. Physicians and patients should be aware that
autoimmune bullous diseases may not require lifelong treatment. However, patients with auto-
immune bullous diseases should be monitored in their clinical remission and blood analysis for
autoantibody detection. Both help to evaluate the risk of disease flaring up.
3. Systemic treatment of pemphigus group
3.1. Systemic induction therapy
Systemic induction therapy should be started with systemic immunosuppressive medication
in combination with topical antiseptic agents and possible topical corticosteroids. Only in
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exceptional cases of limited disease and minor severity, monotherapy with topical corticoste-
roids or with topical calcineurin inhibitors may be considered. However, patient clinical
symptoms and the presence of autoantibody level should be evaluated.
Corticosteroids are the mainstay therapy in management of mild to severe disease of all sub-
types of pemphigus due to their rapid effects, resulting in a significant improvement in
morbidity and mortality rates. Corticosteroids are regarded as a first-line treatment for initial
management of pemphigus. Prednisolone equivalent of 0.5–1.5 mg/kg/day is recommended as
the initial dose in induction therapy, depending on disease severity, patient age, and
comorbidities. To control pemphigus foliaceus, generally, lower doses than that of pemphigus
vulgaris are required. If the control of the disease is not achieved within 2 weeks, a higher
prednisolone equivalent up to 2.0 mg/kg/day is optional. In severe and recalcitrant disease, a
daily dose above 100 mg should be utilized intravenously in pulse therapy mode. Doses of
pulse therapy are not standardized. Methylprednisolone 10–20 mg/kg/day (250–1000 mg) is
administered every day on 3 consecutive days in intervals of 3–4 weeks, subsequently for 6–
8 weeks [7]. Another choice is to use dexamethasone 2–5 mg/kg (50–200 mg). The aim of
pulsing is to achieve more rapid and effective disease control compared with conventional
oral dosing. However, adverse effects are common and dose related. The dosing schedule is
advocated according to disease severity. Patients with mild disease are treated with initial
prednisolone equivalent 40–60 mg/day, and more severe cases with 60–100 mg/day. If the
patient does not respond within 5–7 days, the dose should be increased in 50–100% increments
until disease control is achieved. When a patient does not respond well to systemic predniso-
lone therapy even at higher doses, the change of prednisolone to other oral corticosteroid (e.g.,
betamethasone, dexamethasone or methylprednisolone) might improve patient’s condition [8].
Autoantibody titers fall with clinical healing, but the decrease of autoantibody titer is slower
than clinical improvement.
Systemic corticosteroids can be combined with an immunosuppressive adjuvant agent at the start
of therapy, especially in individuals with increased risk of corticosteroid-related side effects
(Table 1). However, the addition of an adjuvant agent in induction therapy was not exactly
confirmed and documented. Adjuvant drugs are usually administered in combination with a
systemic corticosteroid to reduce related adverse and side effects and increase the immunosup-
pressive efficacy of medication. Their corticosteroid-sparing effect may lead to corticosteroid-free
remission. If an adjuvant agent is utilized at the induction phase of treatment combined with
corticosteroid, its efficacy should be expected in within approximately 1 month, depending on the
specific adjuvant drug. Some authorities believe that the time to induce remission is shorter in
high dose oral prednisolone monotherapy than with low dose oral prednisolone combined with
an adjuvant drug. Moreover, rapidly progressive lesions necessitate a high dose of corticosteroid
for early and adequate control of the disease. However, the significantly higher dose directly
correlates to increased rates of treatment-associated adverse events. Therapy-related side and
adverse effects and complications should be expected in prolonged administration of more than
4 months or at prednisolone dose ≥10 mg/day [1].
In severe and refractory cases, the induction therapy can be started with second-line adjuvant
agents’ rituximab, intravenous immunoglobulins or by immunoadsorption.
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3.2. Systemic consolidation therapy
Systemic consolidation therapy in pemphigus vulgaris starts as soon as control of disease
activity is achieved and approximately 80% of lesions are healed. Tapering of the corticoste-
roid can start by approximately 25% of the dose at 7–14-days intervals. If tapering reached a
prednisolone equivalent of 20 mg/day, slower tapering at 2- to 4-week intervals is
recommended. If relapse of the disease develops in the consolidation phase, systemic corti-
costeroid dose should be returned to two reduction intervals before. If control of disease
activity is achieved within 14 days, tapering of corticosteroid can continue. If control of
disease activity is not achieved, it is recommended to return to the initial systemic cortico-
steroid dose [1, 7].
Immunosuppressive efficacy of systemic corticosteroid is enhanced, if combination with other
immunosuppressive adjuvant is used, including azathioprine, mycophenolate mofetil, cyclo-
phosphamide, methotrexate or dapsone. Most adjuvant immunosuppressive drugs act more
slowly than corticosteroids and their efficacy manifests within several weeks. Therefore, adju-
vant agents are most frequently utilized after control of disease activity is achieved.
First-line therapy Dose initial therapy
Prednisolone 0.5–1.5 mg/kg/day
Second-line therapy (first-line adjuvant agent)
Azathioprine 1–3 mg/kg/day
Mycophenolate mofetil 2 g/day
Mycophenolic acid 1440 mg/day
Third-line therapy (second-line adjuvant agent)
Cyclophosphamide 500 m i.v. bolus or 2 mg/kg/day orally
Methotrexate 10–20 mg/week
Dapsone 100 mg/day or up to ≤1.5 mg/kg/day
Anti-CD20 monoclonal antibody (rituximab) 2  1 g i.v. (2 weeks apart) or 4  375 mg/m2 (each 1 week apart)
Intravenous immunoglobulin G 2 g/kg/4 weeks i.v.
Immunoadsorption 2 cycles a 4 days, 4 weeks apart
Pemphigus herpetiformis
Dapsone + prednisolone 100–300 mg/day + low dose of prednisolone
IgA pemphigus
Dapsone + prednisolone 100–300 mg/day + low dose of prednisolone
Acitretin 50 mg/day
First-line therapy uses systemic corticosteroid that has rapid immunosuppressive efficacy. Second-line therapy is used in
refractory disease or in contraindications to systemic corticosteroids. First-line adjuvant agents have corticosteroid-
sparing effect. Second-line adjuvant agents are used in refractory disease or in contraindications to first-line adjuvant
agents.
Table 1. Systemic treatment of pemphigus group.
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3.3. Systemic maintenance therapy
In the systemic maintenance phase, systemic corticosteroid is gradually tapering to the lowest
level that suppresses the appearance of new lesions, with the goal being to discontinue all
medications eventually. If a patient is treated with two or more immunosuppressive drugs,
these should be tapered one at a time. Corticosteroid tapering continues from the consolida-
tion phase and other immunosuppressive agents should be tapered later. Tapering too rapidly
increases the chance of relapse, while tapering too slowly may lead to medication-related side
effects. In complete remission on therapy, the patient receives minimal therapy, i.e., less than
10 mg/day prednisolone and/or minimal adjuvant therapy for at least 2 months. Minimal
adjuvant therapy is defined as half of the initial dose. The systemic corticosteroid dose is
reduced by approximately 25% at 7 to 14 days and gradual conversion to an alternate day
schedule once the daily dose is at 10–8 mg. The rate of medication tapering is based on the
clinical outcome and physician’s experience. If autoantibody does not continue to fall and new
lesions (one to three) appear while medication is being tapered, new lesions could be treated
with intralesional or highly potent topical corticosteroid while maintaining the patients on
their current dose of systemic medications [9]. The appearance of three to five lesions in a
month that do not heal spontaneously within 1 week is regarded to be a relapse of disease in
the maintenance phase. The dose of medication should be returned to the dose given two
reduction intervals before until control of the disease is achieved.
Remission on minimal maintenance dose, negative autoantibody level, and negative DIF data are
indicating markers for discontinuation of immunosuppressive medication. It is recommended to
control the DIF data, if the patient is on a minimal maintenance dose for about 6–12 months with
total clinical clearance [1]. Healthy skin from the sacral area not irradiated by the sun and covered
with suits is a suitable sample for DIF. In addition, discontinuation of medication can ultimately
be compassed in most patients. The proportion of patients in whom discontinuation of immuno-
suppressive therapy can be achieved increases steadily with time, and it can be discontinued in
approximately 50% of patients after 3 years and in 75% of patients after 10 years [10, 11].
Prolonged treatment lead to high cumulative doses of corticosteroids and adjuvant drugs and
medication-related side and adverse effects.
3.4. Adjuvant drugs
The application of adjuvant drugs into the therapy regimen of autoimmune bullous skin
disorders allows the period of high dose corticosteroids application to be shortened. Adjuvant
drugs have a corticosteroid-sparing effect, following with a decrease of corticosteroid-related
side and adverse effects and an increase in the immunosuppressive efficacy of the regimen.
Recently, several adjuvant agents have been utilized as an initial treatment in combination
with corticosteroids.
3.4.1. Azathioprine
Among adjuvant agents, azathioprine is regarded as a first-line adjuvant with corticosteroid-
sparing efficacy, most frequently used to treat autoimmune bullous disease including
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pemphigus. Azathioprine is a purine analog with specific activity to lymphocytes and is more
selective for T-cells than B-cells [12]. Azathioprine interferes with purine synthesis and metab-
olism, leading to delayed action of drug, as it usually takes at least 1–2 months [13].
Extensive experience with azathioprine refers to good efficacy, tolerability and safety profiles.
One study compared four regimens in 120 patients with pemphigus vulgaris. The efficacy of
prednisolone was enhanced, when the drug was combined with an immunosuppressive adju-
vant. Among adjuvants, azathioprine showed the highest corticosteroid-sparing effect. Other
compared adjuvants were mycophenolate mofetil, intravenous cyclophosphamide, and prednis-
olone alone. In general, azathioprine is believed to be more effective than corticosteroid alone,
both in terms of mortality and morbidity rates [14]. Another review evaluated 20 clinical studies
comprehending data of 826 patients with pemphigus vulgaris and pemphigus foliaceus and
confirmed the very good corticosteroid-sparing effect of azathioprine better than cyclophospha-
mide. However, azathioprine did not increase the remission rate [15]. The next review evaluated
10 clinical studies that comprehended data of 559 participants treated with various adjuvants,
including azathioprine, mycophenolate mofetil, cyclophosphamide, intravenous immunoglobu-
lins, plasma exchange and infliximab. All adjuvants collectively decreased the risk of relapse by
29%, but all of them did not increase the remission rate [16]. The corticosteroid-sparing effect of
azathioprine was also confirmed in a review study of 11 studies with 404 participants [17].
The activity of thiopurine methyltransferase (TPMT) should be evaluated before the beginning
of therapy with azathioprine. Decreased activity of TPMT takes place in induction of an
adverse event. In the Japanese population, an adverse event of azathioprine was associated
with gene mutation of inosine triphosphate pyrophosphohydrolase (ITPA), another enzyme
metabolizing azathioprine [18]. It is recommended to start therapy with a low initial dose of
azathioprine 50 mg/day to detect idiosyncratic reactions. If the activity of TPMT shows normal
levels, the dose can be increased to 1–3 mg/kg/day depending on the clinical outcome. If TPMT
activity shows an intermediate or low level, it should be applied in a lower dose up to 0.5–
1.5 mg/kg/day. Patients with insufficiency of TMPT activity are at risk and should not be
treated with azathioprine because they may experience rapid bone marrow suppression after
initiation of therapy. Furthermore, some patients may experience complications despite nor-
mal TPMT activity. All patients at risk of severe toxicity should undergo close monitoring of
clinical and hematologic parameters, including liver enzyme levels. Likewise, an abrupt
increase in liver enzymes observed soon after administration of azathioprine is a clue to
deficient TPMT activity. In addition, concurrent therapy with TPMT-inhibiting drugs, such as
allopurinol or sulfasalazine, can also increase the risk of myelotoxicity [19].
If the clinical outcome improves, the lowest effective dosage should be administered. If no
improvement occurs within 3 months, the drug should be withdrawn and changed for another
adjuvant agent. However, in patients who achieve improvement in clinical outcome, care
should be taken in monitoring for myelosuppression and hepatotoxicity. It is strictly
recommended to monitor the full blood count weekly over a period of 8 weeks, then at a
minimum of once every 3 months. In addition, liver functions should be monitored.
Adverse drug reactions with azathioprine occur in 15–30% of patients and include leucopenia,
thrombocytopenia, anemia, pancytopenia, and hepatotoxicity [13]. Long-lasting immunosuppression
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increases the risk of infections and only a minor increase of neoplasia, mostly lymphoma [20].
In addition, alopecia, rash or gastrointestinal disturbances (nausea, vomiting, anorexia, diar-
rhea, aphthous stomatitis, and pancreatitis) can be observed. In pregnancy and breastfeeding,
azathioprine is contraindicated due to the risk to the child [21].
Extensive experience with azathioprine refers to good efficacy and safety profile and the drug is
recommended as a first-line adjuvant agent with corticosteroid-sparing immunosuppressive in
the second line of treatment in moderate to severe pemphigus vulgaris and pemphigus foliaceus,
and other types of pemphigus.
3.4.2. Mycophenolate mofetil and mycophenolic acid
Mycophenolate mofetil is an esterified prodrug of mycophenolic acid. Both belong to first-line
adjuvants. Mycophenolic acid is an active metabolite that selectively inhibits inosine mono-
phosphate dehydrogenase, an enzyme involved in de novo synthesis of quanosine nucleotides.
Mycophenolate mofetil inhibits T-cells and B-cells proliferation, and antibody production by
B-cells [22]. The induction of disease remission often requires at least 8 weeks of treatment.
One study compared combined therapy of corticosteroid with mycophenolate mofetil or
azathioprine. Both adjuvants demonstrated similar efficacy, sparing effect, and safety profiles
[23]. Very good efficacy was demonstrated in 18 patients with pemphigus vulgaris treated
with mycophenolate mofetil using a conventional dose, with 89% of them achieving complete
disease control. The average time to achieve 75% clearance of lesions was 4.5 months. Three
patients discontinued all immunosuppressive therapy, including mycophenolate mofetil, in an
average of 3 years [24]. Another review of 11 clinical studies comprehended data of 404
patients with pemphigus vulgaris and pemphigus foliaceus and evaluated mycophenolate
mofetil as more effective in achieving disease control than azathioprine [17]. Mycophenolate
mofetil is regarded to be less myelosuppressive and hepatotoxic than azathioprine [20].
Adverse drug reactions include especially gastrointestinal events such as diarrhea, nausea,
vomiting, following with infections, leucopenia, and anemia. Hematologic findings are dose-
related and reversible. In general, mycophenolate mofetil is well-tolerated and serious adverse
effects are rarely observed. The recommended dose of mycophenolate mofetil is 0.5–2 g/day or
mycophenolic acid at 1440 mg/day. However, increasing the daily dose by 1 capsule (500 mg)
per week is recommended until the final dose of 2 g/day to evoke better gastrointestinal
tolerance. Enteric-coated mycophenolate sodium was prepared to minimize gastrointestinal
side effects and improve quality-of-life and compliance to treatment [25]. Mycophenolate
mofetil is contraindicated in pregnancy because of the increased risk of miscarriage and
congenital malformations [21]. Mizoribine is a newly developed immunosuppressive agent
affecting purine synthesis similar to mycophenolate mofetil and can be utilized in patients
with autoimmune bullous diseases, including pemphigus vulgaris [26]. It is suspected that
mizoribine would have lower toxicity and higher tolerability than other immunosuppressants,
such as azathioprine or cyclosporine.
Mycophenolate mofetil displayed a very good safety and efficacy profile as a first-line adju-
vant agent and could replace azathioprine as an antimetabolite adjuvant of choice in the
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second-line treatment of many autoimmune and inflammatory diseases, including moderate to
severe pemphigus vulgaris and pemphigus foliaceus as well as other types of pemphigus.
3.4.3. Cyclophosphamide
Cyclophosphamide is a second-line adjuvant agent that can be utilized when first-line adju-
vant agents fail to evoke remission or a corticosteroid-sparing effect. Cyclophosphamide is an
alkylating agent with highly effective immunosuppressive activity. It alkylates DNA at various
positions, resulting in cell cycle arrest, DNA repair, and apoptosis. Proliferating tissues with a
high mitotic rate are the most susceptible to cyclophosphamide. However, its activity is not cell
cycle-dependent. Both cellular and humoral immunity is suppressed [27]. The toxicity is
significantly higher than that of azathioprine and therefore it is reserved for the most severe
and refractory diseases.
Several studies demonstrated that oral cyclophosphamide is an effective adjuvant in the treat-
ment of severe and refractory pemphigus vulgaris and pemphigus foliaceus in dose 2–2.5 mg/
kg/day each morning followed by massive oral hydration of at least 2–3 L of fluids [28]. One
retrospective study evaluated therapy in 101 patients with pemphigus vulgaris. Authors com-
pared oral cyclophosphamide, azathioprine, and cyclosporine. Cyclophosphamide was evalu-
ated as the drug with the best remission and relapse rates [29]. Another comparative study of 16
patients with pemphigus vulgaris showed a faster onset of activity in cyclophosphamide than
azathioprine, but the evaluation of efficacy in both did not differ [30]. One prospective study of
11 patients with pemphigus compared dexamethasone-cyclophosphamide pulse therapy with
oral corticosteroid (methylprednisolone)-azathioprine therapy in conventional doses and failed
to find significant benefits between these two regimens, besides fewer recurrences in pulse
therapy with cyclophosphamide [31]. Cyclophosphamide showed a very good corticosteroid-
sparing effect [29].
Several dosing schedules have been developed to minimize cumulative dose and susceptibility
to adverse events. These include monthly intravenous administration (500 mg) in conjugation
with low oral dose daily between infusions (2.0 mg/kg/day). A single dose of intravenous
immunoablative therapy can also be used. However, daily oral cyclophosphamide results in
the highest cumulative dose. On the other hand, continuous daily exposure provides optimal
immunosuppression. In severe recalcitrant pemphigus vulgaris, a combined regimen of pulsed
intravenous cyclophosphamide with corticosteroid could be used. The pulse regimen consists
of the intermittent administration of a high dose of corticosteroid and cyclophosphamide,
usually as three daily doses of corticosteroid (dexamethasone 100 mg or methylprednisolone
500–1000 mg) and a single dose of cyclophosphamide (500 mg). Such corticosteroid-
cyclophosphamide pulses can be administered once a month over a period of several months.
Between these pulses, the patient receives cyclophosphamide 2 mg/kg/day.
In cyclophosphamide therapy, adverse events are frequent, including hemorrhagic cystitis and
high susceptibility to infection. Mutagenic activity increases an individual’s lifetime risk for
transitional cell carcinoma of the bladder and hematologic malignancies. This risk is propor-
tional to the cumulative dose of the drug. Moreover, acute myelosuppression can be developed
in 6–10 days and recovered in 14–21 days after discontinuation of cyclophosphamide.
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However, another adverse gastrointestinal event may develop, including mucosal ulcers,
nausea, vomiting, stomach pain, and diarrhea. Potential gonadal toxicity is associated with
amenorrhea, azoospermia, and infertility [19]. In addition, cardiotoxicity, hepatotoxicity, inter-
stitial lung fibrosis, darkening of the skin and nails, alopecia, changes to hair color and texture,
and lethargy may develop.
The efficacy and safety profile raised cyclophosphamide as a second-line adjuvant drug of
choice in the third line of treatment in severe and refractory pemphigus vulgaris and pemphi-
gus foliaceus.
3.4.4. Methotrexate
Methotrexate was primarily developed to treat malignancies. Recently, methotrexate has been
used as an immunosuppressive and anti-inflammatory agent. Methotrexate is a folate antago-
nist that competitively inhibits dihydrofolate reductase, resulting in blocking of several folate-
dependent enzymes integral to DNA synthesis. The synthesis of purine and pyrimidine nucle-
otides is involved, which in turn is necessary for synthesis of DNA and RNA. The drug affects
the S-phase of the cell cycle, thus inhibiting rapidly proliferating cells, including malignant,
hematopoietic, and mucosal [32]. However, methotrexate inhibits cell proliferation especially
at higher doses. At lower doses, the drug has anti-inflammatory activity. The mechanism of
anti-inflammatory activity is not fully understood. It could be mediated via a pathway sepa-
rate from folate antagonism. The drug may evoke the inhibition of polyamines, resulting in a
net increase in intracellular and extracellular adenosine. Adenosine is a purine nucleoside with
potent anti-inflammatory effect on many different target cells [32, 33].
Methotrexate was the first adjuvant drug to be combined with corticosteroid in the manage-
ment of autoimmune bullous diseases. A retrospective analysis of 7 clinical studies evaluated
the efficacy of methotrexate in 116 patients with pemphigus vulgaris. Of those, 83% showed
clinical improvement. Fourteen patients achieved total remission and were off therapy by a
mean of 2.6 years after discontinuation of methotrexate and systemic corticosteroid. Nausea
and infection were the most frequent side effects and one patient died due to bronchopneu-
monia [34].
At present, a methotrexate dose of 10–20 mg/week is used orally to treat autoimmune bullous
diseases, including pemphigus vulgaris. A test dose of 2.5–5 mg is recommended at the initiation
of therapy. If the drug is tolerated, the dose can be escalated to the therapeutic dose. Methotrexate
has good oral bioavailability and is akin to parenteral administration. However, interindividual
absorption variability exists. Therefore, in patients with an inadequate answer to oral administra-
tion, a switch to intramuscular dosing is recommended. Folic acid is used to decrease the
deleterious side effects of methotrexate and can be used the next day in a dose of 1–5 mg or daily.
Folic acid supplementation can prevent folate deficiency, improving tolerance and preventing
anemia, neutropenia, stomatitis, and oral ulcers. Methotrexate is a corticosteroid-sparing agent
with delayed, beneficial effect on oral lesions, whereas the cutaneous lesions usually respond
very well and rapidly. Methotrexate may interact with nonsteroidal anti-inflammatory drugs,
trimethoprim-sulfamethoxazole, sulfasalazine and phenytoin, resulting in increased time to elim-
inate methotrexate. These interactions may result in severe bone marrow toxicity. Adverse events
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involving methotrexate are usually mild and self-limiting or preventable. When an adverse event
occurs, the dosage should be decreased or withdrawn. In a relatively brief time, the adverse
effects may consolidate in a normal condition. The most frequent adverse effects include nausea,
anorexia, vomiting, diarrhea, fatigue, and malaise. Fatigue and nausea may be minimized by
taking the drug before bedtime and by folic acid supplementation. In general, adverse effects are
dose-dependent and usually appear around the initiation of therapy. A serious adverse event is
myelosuppression, which can develop in patients with potential risk factors like renal insuffi-
ciency, senescence, concomitant serious illness or infection, drug overdose or drug interaction. In
severe cases, myelosuppression is considered a potentially fatal condition, but usually improves
after dose reduction or withdrawal. Mucositis is regarded as precursor of developing pancytope-
nia, and should be taken seriously. Patients with significant pancytopenia (WB ≤ 3000, Hg ≤ 11,
platelets ≤ 50,000) should be treated immediately with intravenous leucovorin (folinic acid), the
antidote to methotrexate, that is able to bypass dihydrofolate reductase [35]. In addition, hepato-
toxicity, resulting in fibrosis and cirrhosis, is a serious adverse event associated with long-term
administration of methotrexate, when the cumulative dose reached 9.5–26 g [34]. Obesity, diabe-
tes mellitus and excessive alcohol consumption are regarded as risk factors for liver toxicity.
According to the Manchester protocol, serum procollagen III aminopeptide (PIIINP) assay may
be used to monitor liver toxicity resulting from methotrexate toxicity [36]. If PIIINP assay is not
approachable, some authors predict a liver biopsy. A liver biopsy is recommended when the total
cumulative dose reaches 3.5–4.0 g [37]. Monitoring of liver function and bone marrow is
recommended to be repeated regularly to avoid myelosuppression and hepatotoxicity. Metho-
trexate is contraindicated in pregnancy due to its teratogenic and abortifacient properties. More-
over, it causes reproductive toxicity and decreases the sperm account [38]. Mucocutaneous
toxicity occurs more commonly in patients without adequate folic acid supplementation. In
severe cases, it can be associated with diarrhea and myelosuppression. Mucocutaneous toxicity
can start with mucositis or very painful oral ulceration. More rarely, ulceration of the skin could
be an early harbinger of methotrexate toxicity.
Methotrexate is a corticosteroid sparing agent and is recommended as a second-line adjuvant
in the third-line treatment of moderate to severe pemphigus vulgaris and pemphigus foliaceus.
The drug is relatively inexpensive.
3.4.5. Dapsone
Dapsone is a sulfone-derived drug that primarily possesses both antimicrobial and antiprotozoal
activities. Additionally, dapsone has anti-inflammatory properties like non-steroidal anti-
inflammatory drugs. Dapsone suppresses neutrophilic infiltration by inhibition of neutrophil
activation and recruitment through many different pathways [39].
One multicenter randomized, double blind study confirmed the glucocorticoid-sparing efficacy
of dapsone in 19 patients with pemphigus vulgaris. Seventy-three percent of patients treated
with dapsone achieved remission [40]. A retrospective review study analyzed 35 case series and
case reports comprehending data of 427 patients with autoimmune bullous disease. Among
them were 55 patients with pemphigus (32 patients with pemphigus vulgaris and 14 with
pemphigus foliaceus). Dapsone was evaluated as an effective and useful corticosteroid-sparing
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agent in therapy of autoimmune bullous disease, including pemphigus. Adverse events were
dose-dependent and reversible. The most frequent adverse event was hemolysis and concomi-
tant anemia secondary to hemolysis [41].
The recommended dose of dapsone is 100 mg/day or up to ≤1.5 mg/kg/day. Prior to start
dapsone therapy, glucose-6-phosphate dehydrogenase deficiency should be excluded, and cell
blood counts, renal and liver functions must be examined. During dapsone therapy, cell blood
counts including reticulocyte, leukocyte and platelet, and the level of methemoglobin, should
be regularly monitored. It is recommended to start dapsone therapy with a low dose of 0.5 mg/
kg/day. If the drug is tolerated, the dose can escalate slowly up to the effective dose [39]. A
rapid enhancement of medication may result in a severe hemolytic anemia. Adverse events are
dose-dependent and transient. However, frequent adverse effects include hemolytic anemia
and methemoglobinemia which may necessitate halting treatment. A high dose of vitamin C
supplementation can evoke better tolerability of dapsone, including a drop in the methemo-
globin level. In addition, headache is a common adverse event. More serious complications are
hepatitis, hypersensitivity syndrome and agranulocytosis. Peripheral neuropathy is a rare
adverse event and may involve both motor and sensory nerves [39]. Most complications are
referred in the first 3 months of treatment. Precaution should by mentioned in the second
trimester of pregnancy, when dapsone should be reduced or stopped. If dapsone is not toler-
ated, it could be replaced with other sulfonamides, e.g., sulfapyridine (1.5 g/day) or
sulfamethoxypyridazine (0.25–1.5 g/day). In addition, sulfonamides are contraindicated in
breastfeeding women because they may induce hemolytic anemia in an infant.
Dapsone is recommended as a second-line adjuvant agent to treat mild to severe pemphigus
vulgaris and pemphigus foliaceus, especially in the maintenance phase of their management.
The drug is a corticosteroid-sparing agent recommended with either low or intermediate doses
of systemic corticosteroid and may allow tapering or discontinuation of corticosteroid doses.
Dapsone is regarded as a third-line therapy in pemphigus diseases.
3.4.6. Anti-CD20 monoclonal antibody (rituximab)
Rituximab is a murine/human chimeric monoclonal antibody, targeting the CD20 molecule
found on the cell surface of B-cells of various maturate stages up to the preplasma cell stage.
Stem cells or B-cell progenitors, plasmablasts, and plasma cells, do not express the CD20
molecule and do not respond to rituximab. Among several mechanisms involved in patho-
physiology of autoimmune bullous disease, rituximab exerts B-cell cytotoxic activity mainly
through antibody-dependent cell-mediated cytotoxicity, resulting in depletion of B-cells that
presumably produce pathogenic antibodies. Depletion of B-cells persists in circulation for
6–12 months. However, after the rituximab treatment, the B-cell count returns to normal levels.
Even so, replacement of B-cells is not associated with relapse in a considerable number of
patients with autoimmune disease. These data suggest that rituximab-mediated depletion of
B-cells may influence also other cells participating in immune tolerance and homeostasis. In
addition, the depletion of B-cells may participate in decreasing resistance against infection.
One study demonstrated a significant reduction of T regulatory cells after rituximab therapy.
This event may be due to increased skin homing of these cells [42].
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Primarily, rituximabwas used for treating non-Hodgkin’s B-cell lymphoma. The use of rituximab
in pemphigus began after a marked improvement in lymphoma-associated paraneoplastic pem-
phigus [43]. Rituximab has a late onset of action to control acute disease and produces an initial
clinical response in 69 weeks or less. It should therefore, be used as an adjuvant agent combined
with systemic corticosteroids and/or another adjuvant agent. Two FDA protocols for rituximab
management can be used to treat autoimmune bullous disease, including pemphigus. The
lymphoma protocol utilizes four infusions of rituximab 375 mg/m2 given in four consecutive
weeks, a week apart. The rheumatoid arthritis protocol uses two infusions at a dose of 1 g, given
2 weeks apart. Even though both protocols are effective, the rheumatoid arthritis protocol could
prove better because both rheumatoid arthritis and pemphigus are autoimmune diseases. One
retrospective review report evaluated 42 clinical studies comprehending data of 272 patients
with pemphigus vulgaris who have been treated with rituximab. Data of the review study
showed that a complete remission was achieved in 66.6% of patients on the lymphoma protocol
and 75% on the rheumatoid arthritis protocol within an 18-month follow-up. During this period,
11.1% of patients treated with the lymphoma protocol achieved remission and were off therapy
and 33.3% on minimal immunosuppressive therapy. Meanwhile, on the rheumatoid arthritis
protocol, 53.3% of patients achieved remission off therapy and 17.4% on minimal immunosup-
pressive therapy. A partial response was observed in 12.8% of patients on the lymphoma proto-
col, and in 23.9% of patients on the rheumatoid arthritis protocol. The relapse rates were 22.8%
on the lymphoma protocol and 35.9% on the rheumatoid arthritis protocol. The incidence of
serious infections was 3.9% on the lymphoma protocol and 15.2% on the rheumatoid arthritis
protocol. The mortality rate on the lymphoma protocol was 2.2% and 1.1% on the rheumatoid
arthritis protocol [44]. Remarkable differences were observed in patient’s response between both
protocols. At present, the reason for protocol differences cannot be detected. Rituximab has a
corticosteroid-sparing effect. In the future, a modified protocol for autoimmune bullous disease
should be designed and evaluated. Some patients can develop resistance and do not respond to
the rituximab regimen. The resistance can be due to the autoantibody to rituximab that interferes
with drug binding or the pharmacokinetics of the drug could be changed by other ways.
Intravenous administration of rituximab should be initiated with premedication before each
infusion using an antipyretic, e.g., paracetamol 1000 mg orally, or antihistamine. Prior to the
first infusion, prednisolone 100 mg orally is advised. Rituximab infusion should be adminis-
tered over 4–5 h. One cycle of rituximab may be repeated. Pathological lesions start to heal
within just a few weeks after the first rituximab infusion and maximal effect can be expected
after 3–4 months. Remission rates after the first-treatment cycle reached 76%. Repeating treat-
ment further increased the remission rates to 91% [45].
Rituximab is generally well tolerated, and serious adverse effects are rare. Infusion-related reac-
tions include anaphylaxis, hypotension, fever, chills, headache, weakness, nausea, pruritus and
rash. Infusion-related reactions could be ameliorated by premedication before each infusion, then
by decelerating or temporarily stopping of infusion. In addition, deep venous thrombosis of the
lower limb and pulmonary embolism are serious complications. A frequent adverse event is the
infection afflicting around 30% of patients, with a larger account of bacterial than viral infections.
Moreover, herpes zoster is reported in several cases. Higher rates of infection could be influenced
by concomitant treatment with an immunosuppressive agent, including corticosteroids. Another
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serious adverse event may accompany rituximab treatment like Pneumocystis carinii infection
causing pneumonia or septic shock, which may cause death.
In addition, rituximab is an effective drug in controlling recalcitrant disease and is recommended
as the second-line adjuvant to treat severe refractory autoimmune bullous diseases, including
pemphigus vulgaris, pemphigus foliaceus and pemphigus paraneoplastic. Complications such as
fatal infections and other serious adverse events place the drug to the last resort treatment
restricted for severe and refractory cases. Rituximab is recommended when other second-line
adjuvant agents, including immunoadsorption and intravenous immunoglobulins, fail in the
treatment or patients have multiple relapses. Despite the threat of serious adverse events, several
reports would like to recommend rituximab as a first-line treatment accompanied with low dose
of corticosteroids in patients with moderate to severe pemphigus [46]. The regimen proved
effective and caused fewer adverse events than the regimen using corticosteroids alone [47]. First-
line treatment with rituximab should be regarded in pemphigus patients, who are contraindicated
to corticosteroid and other immunosuppressive therapy [47–49]. In near future, a new protocol for
pemphigus patients should be elaborated and confirmed in clinical trials. Another study
recommended rituximab combined with intravenous immunoglobulins as a first-line therapy in
severe and refractory pemphigus. This regimen can evoke prolonged remission and could be used
when corticosteroids and immunosuppressive adjuvants are contraindicated [50].
Research into biologic agents discovered newmolecules that could be used in the management
of autoimmune bullous diseases. New humanized anti-CD20 monoclonal antibodies modify or
bind to different sites to the target molecules. The newmolecules escalate activity and possess a
higher efficacy in preclinical trials. All of them are of second or third generations of humanized
anti-CD20 monoclonal antibody. Furthermore, efficacy, safety, and tolerability should be eval-
uated in clinical trials. Among them, veltuzumab is an anti-CD20 monoclonal antibody that is
largely identical to rituximab. Its advantage is subcutaneous administration. Obinutuzumab
possesses 50-fold greater binding and stronger induction of apoptosis than rituximab resulting
in a rapid and profound B-cell depletion during the first infusion. Ofatumumab possesses a
superior and longer-lasting cytotoxic effect than rituximab. It is used intravenously.
Ocaratuzumab has a higher binding affinity and 10-fold higher cytotoxicity, which results in
smaller dosage using subcutaneous administration. PRO131921 has 30-fold higher binding
affinity and 10-fold higher cytotoxicity than rituximab. It is used intravenously [51]. New
humanized anti-CD20 monoclonal antibodies require further clinical trials to evaluate and
establish dosing, efficacy and safety, including the monitoring of potential adverse events.
According to the guidelines rituximab is recommended as a second-line adjuvant for severe
and refractory pemphigus vulgaris. Rituximab can be utilized, when the failure of conven-
tional therapy is present, e.g., severe adverse events in conventional therapy, contraindications
to use a high dose of other immunosuppressive therapies and progressive and rapid
uncontrolled disease. Rituximab is regarded as a third-line therapy in pemphigus diseases.
3.4.7. Intravenous immunoglobulin G
Primarily, high intravenous immunoglobulin G was used to treat primary immunodeficiencies,
immune thrombocytopenic purpura, Kawasaki disease, chronic B-cell lymphocytic leukemia,
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pediatric AIDS and others. In recent years, intravenous immunoglobulin has been used in the
treatment of autoimmune and chronic inflammatory diseases, including autoimmune bullous
diseases.
Immunoglobulin preparations are a special type of biologic treatment obtained from the pooled
plasma of multiple healthy donors amounting 3000–10,000. Purified, pooled plasma contains
natural antibodies of the IgG subclass. Natural autoantibodies are believed to play a role in
maintaining immune homeostasis. Moreover, it contains a repertoire of the all IgG antibodies from
populations as a mirror of the interaction of intravenous immunoglobulin individuals with exter-
nal pathogens. Plasma may contain also natural autoantibodies, which presents the risk of prepa-
ration, but a considerable number of donors assists in dilution of these molecules. In addition,
pooled plasma may contain a minimal refused amount of IgA or IgM. The guidelines for
processing plasma are precise and stringent to avoid especially viral and bacterial contaminations.
For this reason, pooled plasma is stored for 60 days and donors are checked for seroconversation
to several pathogens. Individual plasma is also examined by polymerase chain reaction (PCR) for
the presence of HCV RNA, HBV DNA, HIV RNA, HAV RNA and Parvovirus B19 DNA [52].
Only plasma with no pathogens may be collected to the pool preparation. Pulled plasma is
evaluated for the main biological and pharmacological properties, the degree of purity and the
antibody spectrum. The half-life of intravenous immunoglobulin is approximately 3 weeks.
The mechanism of intravenous immunoglobulin assesses several activities involving in activity
complex. The desired response of intravenous immunoglobulin is a rapid decline in patho-
genic autoantibodies and improvement of disease. The intravenous immunoglobulin produces
complement blockade and degradation, Fc-receptor blockade and induces immunomodula-
tory Fc receptors, inhibits B-cells, and alters T-cell function, modulates cytokine production
and cellular migration [53, 54]. Anti-idiotypic antibodies of intravenous immunoglobulin bind
to the pathogenic autoantibodies, helping in their rapid decline. Despite partial knowledge of
the intravenous immunoglobulin activity, the objective mechanism is not fully understood as it
possesses multiple modes of action related to its ability to interact with both innate and
adaptive compartment of the immune system [55]. The intravenous immunoglobulin appears
to have increased clearance of pathogenic IgG autoantibodies, but failed in the suppression of
autoantibody production. However, intravenous immunoglobulin is an adjuvant treatment
and suppression of autoantibody production is operated by corticosteroids and other immu-
nosuppressive adjuvants.
The good efficacy and safety profile of intravenous immunoglobulin was documented in multi-
ple reports, mostly small series. The first multicentric, randomized, placebo-controlled, double-
blind trial of intravenous immunoglobulin confirmed objectively the efficacy of intravenous
immunoglobulin in 61 patients with pemphigus and confirmed a decrease in the autoantibody
level in treated patients. After 7 days, anti-Dsg antibody clearance was documented in 42–74.4%
of patients [56]. One review study evaluated 23 clinical studies and comprehended data of 260
patients with autoimmune bullous disease treated with intravenous immunoglobulin, among
them 191 patients with pemphigus. The intravenous immunoglobulin showed improvement in
245 patients and demonstrated a corticosteroid-sparing effect [57]. In addition, many studies
confirmed intravenous immunoglobulin therapy to have a very good safety profile [58, 59].
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Some authors offer intravenous immunoglobulin not only for severe and refractory pemphigus
vulgaris but also for mild and recalcitrant cases of pemphigus foliaceus [60]. Intravenous immu-
noglobulin may trigger the shift from an intractable condition to remission using a yet not fully
understood mechanism, possibly based on immunomodulation. In recalcitrant pemphigus, a
combination of intravenous immunoglobulin and rituximab is recommended. This combination
could be useful, when response fails to a high corticosteroid dose in combination with adjuvant
immunosuppressive drugs. The mechanism of combined activity of both medications is not
known and should be elucidated. However, rituximab affects pathogenic B-cells and blocks
production of pathogenic autoantibody and intravenous immunoglobulin rapidly declines path-
ogenic autoantibody and influences the innate and adaptive immune system. A 10-year follow-
up study reported long-lasting remission, in 10 patients with refractory pemphigus vulgaris who
have been treated with rituximab combined with intravenous immunoglobulin [9]. The intrave-
nous immunoglobulin preparations are safe and effective and can treat juvenile autoimmune
bullous diseases including pemphigus [61]. Several studies reported good safe and efficacy pro-
files also in pregnancy [38, 62].
An intravenous immunoglobulin response is rapid and administration should be repeated
after 4 weeks initially. If the clinical response is good, the interval between cycles could be
increased gradually to 6 weeks. If the patient does not respond to an intravenous immuno-
globulin therapy, it should be discontinued. In pemphigus vulgaris, the recommended dose is
2 g/kg divided over 3–5 consecutive days. The number of intravenous immunoglobulin cycles
should be repeated depending on the severity of disease. In standard regimen, 3–5 cycles are
recommended to achieve the desired response. However, severity of the disease may require
further intravenous immunoglobulin cycles, without restriction. A repeated dose can be
applied also in relapse of the disease. The intravenous immunoglobulin is a relatively safe
and well-tolerated therapy. Premedication with an antipyretic, e.g., acetaminophen or antihis-
tamine is recommended to avoid adverse events. Oral or intravenous corticosteroid may be
useful, if patient has had a prior reaction or is of elevated risk. The intravenous immunoglob-
ulin should be administered as a long-lasting infusion over 4–5 h.
Systemic adverse events are relatively common, occurring in 20–40% of patients [63], but are
mild and most frequently treatable. Immediate adverse reactions account for 60% of all
adverse events. They occur during or within 6 h of the infusion and could be avoided by
long-lasting infusion. Discontinuation of drug administration may treat immediate adverse
events or the treatment is symptomatic. The most frequent immediate adverse event is head-
ache (8.9–43.8%) [63]. Others include muscles aches, fatigue, chills, and fever. Delayed adverse
reactions develop within more than 6 h to 1 week after administration. Very rare events occur
weeks and months after infusion [63]. A serious adverse event is acute renal failure developing
in patients with renal insufficiency. Risk patients are diabetics, older individuals, or patients
using concomitantly nephrotoxic agents. Sucrose-free intravenous immunoglobulin prepara-
tions are recommended to prevent acute renal failure in risk patients. In these risk patients, an
intravenous immunoglobulin should be administered very slowly and at the lowest effective
dose. Another serious adverse event is thromboembolism associated with a large dose admin-
istered during a fast infusion, which may cause high plasma viscosity. A low dose of intrave-
nous immunoglobulin is imperative also to respect precaution to avoid plasma viscosity.
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Thromboembolism may develop within hours, days, or weeks. Risk patients should be moni-
tored. A very rare and serious adverse event is aseptic meningitis, which may develop within
6 h to 1 week [64]. A minimal amount of IgA intravenous immunoglobulin may evoke the
production of anti-IgA antibody in patients with IgA deficiency. Subsequently, anti-IgA anti-
body can cause immediate anaphylactic or anaphylactoid reactions. An intravenous immuno-
globulin administration may lead to mild hemolytic reactions, due to the presence of anti-A or
anti-B isoagglutinins. Furthermore, mild neutropenia and hyponatremia may occur 2–4 days
after infusion and resolves in less than 1 week [63].
Intravenous immunoglobulin is a second-line adjuvant agent and is utilized with corticosteroids
or other immunosuppressive adjuvant in refractory pemphigus vulgaris and pemphigus
foliaceus. Indication criteria for intravenous immunoglobulin use include the failure of conven-
tional therapy, including significant adverse events in conventional therapy, contraindications to
high doses of other immunosuppressive therapies and progressive and rapid uncontrolled dis-
ease. However, in exceptional cases intravenous immunoglobulin can be utilized as a first-line
treatment, e.g., aseptic bone necrosis, poorly controlled diabetes, advanced osteoporosis, and
cataracts. Intravenous immunoglobulin is regarded as a third-line therapy in pemphigus diseases.
3.4.8. Immunoadsorption
Immunoadsorption is a specific method used to selectively clear pathogenic autoantibodies from
the circulation in autoantibody-mediated disease, including autoimmune bullous diseases.
Immunoadsorption is most frequently used to treat severe and refractory pemphigus vulgaris.
In addition, immunoadsorption also removes immune complexes and produces cytapheresis by
removing inflammatory cells or platelets from the peripheral circulation. In dermatology, the last
can be used to treat pyoderma gangrenosum and psoriasis [65, 66]. Rapid removal of autoanti-
bodies is performed extracorporally by adsorber system, which contains a high-affinity IgG
adsorber or low-affinity IgG adsorber. Both adsorber systems differ with respect to ligands,
matrix, volume of columns, affinity to certain immunoglobulin classes, and reusability. Reusable
adsorbers can be utilized several times for the same patient. The reusable adsorbers are:
Immunosorba® (ligand: ligand Staphylococcal protein A), Ig-Therasorb® (ligand: polyclonal
anti-human antibodies from sheep), and Globaffin® (ligand: synthetic peptide-PGAM146). Reus-
able adsorbers are very effective and produce approximately similar depletion rates [67]. A
number of one-time adsorbers are available, including adsorber Selesorb® (ligand:
dextransulfate), Prosorba® (ligand: Staphylococcal protein A ligand), adsorber IM TR350®
(ligand: tryptophan) and IM PH350® (ligand: phenylalanine), and adsorber Coraffin® (ligand:
combination of synthetic peptides). One-time use adsorbers achieve only a low degree of IgG
decline and usually show little specificity. In the induction phase of therapy, a high-affinity
adsorber is recommended. Autoantibody levels can drop by about 75% utilizing a single proce-
dure with a reusable adsorber system. A decrease about of 95% can be reached at the end of one
cycle; 3 procedures applied over 3 consecutive days. The 3-day procedure is necessary to avoid a
rebound phenomenon, which can appear after the first procedure within 24 h. Autoantibodies
re-diffuse from the tissue to circulation and may reach 40% of the initial autoantibody level [68].
In selected cases, the induction phase could be realized with two consecutive treatments with
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low-affinity adsorbers (e.g., IM TR350® and IM PH350®). This procedure is utilized in individ-
uals with known hypersensitivity towards material used in columns or other materials. After
reaching control of disease, the therapy protocol may continue with subsequent regimen
depending on clinical outcome. Single immunoadsorption can be utilized in weekly intervals
and later in longer intervals. Another modality is to use a 3- to-4-day procedure repeated
monthly. In pemphigus patients, the level of anti-Dsg IgG autoantibody should be evaluated
regularly before and after each individual procedure using ELISA or the titer in indirect immu-
nofluorescence. For pemphigus, a new adsorber system is developing with new highly specific
adsorber selectively binding anti-Dsg IgG antibodies. Recombinant full-length Dsg1 and Dsg3
ectodomains could be used as a ligand in a highly specific adsorber system [69].
In general, immunoadsorption is recommended to treat severe autoimmune disease, including
pemphigus vulgaris in combination with immunosuppressive medication, which can decrease
the production of pathogenic autoantibodies. A retrospective study evaluated data of 82 patients
with pemphigus treated with immunoadsorption. In most patients, reusable systems were
applied with corticosteroids combined with other immunosuppressive drugs, usually azathio-
prine, mycophenolate mofetil, or cyclophosphamide used in conventional doses. Immunoad-
sorption showed a sharp decline of anti-Dsg IgG autoantibodies followed by clinical
improvement [70]. The recent combination of immunoadsorption with rituximab and immuno-
suppressive adjuvants azathioprine or mycophenolate mofetil showed complete remission in
88% of patients with autoimmune bullous diseases, including pemphigus vulgaris (6 patients).
The combination regimen evokes long-lasting improvement in disease outcome. However, the
relapse rate was 13% with an average follow-up of 22 months [71]. In addition, another recent
protocol used immunoadsorption combined with rituximab and dexamethasone pulses in con-
jugation with azathioprine or mycophenolate mofetil, all medication used in conventional doses.
Autoantibody levels declined by more than 50% between the first two cycles. This combined
regimen demonstrated a long-lasting complete remission in 83% of patients. However, at follow
up of 11–43 months a relapse occurred in 26% of patients. In general, the therapy was well
tolerated. However, severe adverse events were documented in 9% of patients, including Staph-
ylococcal sepsis and transient paraplegia of the legs [72]. Immunoadsorption combined with
another immunosuppressive medication showed a corticosteroid-sparing effect.
Adverse events in immunoadsorption are rare and may occur in ≤1% of procedures [68]. Some
severe adverse effects were referred, including deep venous thrombosis, perforating diverticu-
litis, and sepsis [72]. Other adverse effects may develop such as hypotension, bradycardia,
citrate-induced paresthesia, and hypocalcemia [67]. Contraindications for immunoadsorption
include known hypersensitivity towards material used in the columns, treatment with ACE
inhibitors and anticoagulants, severe cardiovascular disease, hypofibrinogenemia, severe sys-
temic infection and body weight under 15 kg.
Immunoadsorption is a second-line adjuvant treatment in autoimmune bullous disease,
including pemphigus. Immunoadsorption is indicated in acute severe disease, if the first-line
treatment proved ineffective or is contraindicated. It is a rapid acting mode of treatment and is
recommended if a rapid response is required. It can also be used in chronic refractory disease,
if the response to standard treatment is inadequate. Immunoadsorption is almost always
Current Therapy in Autoimmune Bullous Diseases
http://dx.doi.org/10.5772/intechopen.71541
189
utilized in combination with immunosuppressive agents that reduce the production of patho-
genic autoantibodies. Systemic corticosteroids are used in high dose orally or intravenously in
bolus and usually are combined with adjuvant immunosuppressant, e.g., azathioprine,
mycophenolate mofetil or cyclophosphamide. Immunoadsorption is regarded as a third-line
therapy in pemphigus diseases.
3.5. Therapy of pemphigus herpetiformis
Pemphigus herpetiformis is a very rare variant in the pemphigus group. The clinical symptoms
resemble dermatitis herpetiformis, but the pathogenic autoantibody IgG is directed mostly
against Dsg1 (occasionally against Dsg3 or desmocollin) [73]. In general, the prognosis is more
favorable than in pemphigus vulgaris. Furthermore, some cases may progress into pemphigus
vulgaris, requiring more aggressive treatment. The therapy regimen of pemphigus herpetiformis
differs from that of pemphigus vulgaris. Dapsone 100–300 mg/day is utilized as a treatment of
choice and can be combined with low dose of systemic corticosteroids. In some severe disease,
improvement of disease could be induced with adjuvant agents that are used to treat pemphigus
vulgaris. Several authors referred to the good efficacy and tolerability of adjuvant agents, includ-
ing azathioprine, mycophenolate mofetil, methotrexate, and cyclophosphamides [74, 75]. In
refractory disease, intravenous immunoglobulin and plasmapheresis may improve the clinical
outcome [73]. One case series report of 8 patients with pemphigus herpetiformis referred to the
minimal clinical improvement of two patients treated with rituximab [74].
3.5.1. Therapy of IgA pemphigus
IgA pemphigus is a very rare variant of the pemphigus group. Disease differs in clinical
affliction from those in the pemphigus group, because of the pustular lesions accompanied by
vesicular ones. Based on clinical and pathological symptoms, it is divided into two variants:
the subcorneal pustular dermatosis type and intraepidermal neutrophilic IgA dermatosis type.
Pathogenic autoantibodies IgA are most frequently directed against desmocollin-1 and
desmocollin-2, -3. Occasionally, IgA autoantibodies can be directed against Dsg1 and Dsg3
[76]. Dapsone is regarded as a first-line treatment. A dose of 100–300 mg/day may improve
clinical symptoms of IgA pemphigus. Dapsone can be combined with a low dose of corticoste-
roids. Refractory cases could utilize etretinate or acitretin (50 mg/day), which can be used
alone or in combination with dapsone [77, 78]. No objective clinical study was performed to
demonstrate the efficacy and tolerability of various therapy regimens in IgA pemphigus. All
recommendations result from clinical experience and small series or case reports.
3.5.2. Therapy of paraneoplastic pemphigus (paraneoplastic autoimmune syndrome)
Paraneoplastic pemphigus or paraneoplastic autoimmune syndrome is a rare condition
with a variety of lesions including florid oral involvement, generalized polymorphous
cutaneous rash resembling various skin disorders and pulmonary involvement. Moreover,
it is associated with malignant neoplasm, most frequently hematoblastosis like non-
Hodgkin’s lymphoma, chronic lymphocytic leukemia or thymoma. However, paraneo-
plastic pemphigus may occasionally accompany benign neoplasia like Castleman’s disease
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or monoclonal gammopathy. Therapy of paraneoplastic pemphigus is almost always very
difficult and suboptimal. The mainstay of therapy is to treat underlying neoplasm. Early
detection and complete resection of neoplasm are of paramount importance. Subsequently,
the removal of neoplasm reduces the production of autoantibodies released from the
tumor. Perioperative intravenous immunoglobulins administration in an obvious dose
(2 g/kg/cycle) is recommended to block autoantibody release from the tumor during sur-
gery [79]. In the case of benign neoplasm, surgical removal ameliorates the condition and
may induce remission of paraneoplastic pemphigus with contemporary decrease of auto-
antibodies within 6–8 weeks [80]. In malignant neoplasm, the prognosis is poor and
depends on the behavior of malignant tumor and development of severe respiratory fail-
ure. The mortality rate is high and ranges from 75 to 90% [80]. The disease may progress
despite surgery and chemotherapy. The prognosis of paraneoplastic pemphigus is obvi-
ously unfavorable with rapid fatal outcome. Treatment of clinical symptoms of paraneop-
lastic pemphigus can be started with systemic corticosteroid, prednisone 0.5–1.0 mg/kg.
Adjuvant agents with corticosteroid-sparing effect including azathioprine, mycophenolate
mofetil, and cyclophosphamide in conventional doses could be used, but they have mostly
potentially tumorigenic properties and their utilization in this condition is limited. How-
ever, patients are often resistant to all conventional therapies and therefore a new therapy
regimen should be sought. The preferred treatment in paraneoplastic pemphigus is
rituximab, which could probably reduce the risk of tumorigenicity. Several studies referred
to the efficacy of rituximab, and some of them about rituximab combined with intravenous
immunoglobulin. In several cases, rituximab was combined with chemotherapy depending
on underlying malignancy [81]. Separaliter administration of intravenous immunoglobulin
may also ameliorate the clinical outcome of paraneoplastic pemphigus and has a cortico-
steroid-sparing effect [59]. Reports about treatment efficacy and tolerability in paraneop-
lastic pemphigus embrace only small series or case reports. In addition, the therapy
protocol embraces aggressive immunosuppressive agents and adverse events are the rule,
including serious infections; among them sepsis is the most frequent cause of death. Respi-
ratory failure, if evident, is a fatal complication. Other fatal complications may result from
underlying neoplasm.
4. Therapy of bullous pemphigoid group
Bullous pemphigoid is the most frequent autoimmune blistering disorder and may last several
years in the absence of treatment followed by total remission. The tendency to relapse is
obligate and can be evoked with/without any risk factors. In general, the course of bullous
pemphigoid is less severe and requires less aggressive treatment than pemphigus vulgaris
(Table 2). However, a very severe course of bullous pemphigoid is not excluded. Relapse of
disease starts with pruritus, consequently followed by skin eruption and occasionally also oral
mucosa involvement. Advanced age in patients supports a large list of comorbidities, includ-
ing cardiovascular, neurological, neoplastic, metabolic and respiratory comorbidities. The
concomitant treatment regimen of comorbidities can hardly influence the choice of treatment
regimen in patients with bullous pemphigoid.
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4.1. Topical and systemic corticosteroids
Bullous pemphigoid can occur as localized or limited disease with mild activity. Potent
topical corticosteroids, e.g., clobetasol propionate 0.05% cream or ointment is often success-
ful to achieve remission. A dose up to 30–40 g/day can be administered twice daily to the
blisters and erosions and perilesional normal skin. Initial treatment should be tapered
15 days after disease control. The tapering regimen embraces the application of corticoste-
roid cream or ointment every 2 days in the second month, then twice per week in the third
month, and then once per week in the fourth month [82]. In relapse, topical corticosteroid
First-line therapy Dose initial therapy
Topical corticosteroid High potency corticosteroid up 30–40 g/day
Prednisolone 0.5–0.75 mg/kg/day
Second-line therapy (first-line adjuvant agent)
Tetracyclines Oxytetracycline 2 g/day, doxycycline 200 mg/day
Azathioprine 1–3 mg/kg/day
Mycophenolate mofetil 2 g/day
Mycophenolic acid 1440 mg/day
Dapsone 100 mg/day or up to ≤1.5 mg/kg/day
Methotrexate 10–20 mg/week
Cyclophosphamide 500 m i.v. bolus or 2 mg/kg/day orally
Third-line therapy (second-line adjuvant agent)
Anti-CD20 monoclonal antibody (rituximab) 2  1 g i.v. (2 weeks apart) or 4  375 mg/m2 (each 1 week apart)
Intravenous immunoglobulin G 2 g/kg/4 weeks i.v.











In mild bullous pemphigoid, a topical high potency corticosteroid may control disease. Systemic corticosteroids are used
in severe disease; compared with pemphigus in lower doses. Tetracycline has an anti-inflammatory efficacy and can
replace corticosteroids in mild bullous pemphigoid. Second-line therapy is used in refractory disease with precaution to
comorbidities. The third-line adjuvant agents most frequently are used in severe mucous membrane pemphigoid or
epidermolysis bullosa acquisita. Antihistamines are used to eliminate pruritus.
Table 2. The treatment of pemphigoid group.
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therapy is increased to the previous level. High-potency topical corticosteroids are also
recommended to support healing of more severe disease. Application can cover the whole
body, sparing the face. However, administration of high potency corticosteroid to a large
body area results in systemic absorption. Despite this, topical application of corticosteroids
decreases adverse events of systemic corticosteroids. Topical corticosteroids are recom-
mended in mild disease, especially when localized. However, topical corticosteroids can
also be utilized in severe disease as they can decrease the dose of systemic corticosteroids. A
large comparative study of 312 patients with bullous pemphigoid demonstrated that mild
regimen of topical corticosteroid (10–30 g/day) induced co-equal clinical improvement as
that of standard regimen (40 g/day). In addition, a mild regimen of topical corticosteroid
allowed a 70% reduction in the cumulative doses of topical potent corticosteroid [83].
Application of topical corticosteroids requires nursing care and should be accompanied by
antiseptic bath, bullae count, and bandaging.
Systemic corticosteroids are amainstay of therapyand are used in lower doses than in pemphigus.
Severe bullous pemphigoid is treated with prednisolone 0.5–0.75 mg/kg/day as an initial treat-
ment. Prednisolone dose ≤0.5 mg/kg/day seems to be ineffective. Initial therapy starts with pred-
nisolone 0.5 mg/kg/day and can be increased to 0.75 mg/kg/day only if control of disease is not
achieved within 1–3 weeks [84]. The major goal in bullous pemphigoid is reducing the patient’s
cumulative dose of systemic corticosteroid. During the consolidation phase, the dose of cortico-
steroid is tapered 15 days after disease control. However, earlier tapering is possible, if the
outcome of diseases is favorable. In the maintenance phase, the lowest dose of corticosteroid
(prednisolone 0.1 mg/kg/day) should be achieved within 4–6 months after initiation of treatment
[82, 85]. If the patient is in remission on maintenance dose for 3–6 months, treatment may be
stopped. Total treatment from initiation phase through consolidation phase up to maintenance
phase, is usually 9–12 months [82]. In the case of relapse, the previous dose of corticosteroid is
recommended.
Topical and systemic corticosteroids are the first-line treatment recommended for mild to
severe bullous pemphigoid.
4.2. Adjuvant therapy
In bullous pemphigoid, immunosuppressive adjuvant therapy is usedwith high precautions and
respect to comorbidities. Adjuvants are used when systemic corticosteroids are limited or
contraindicated, e.g., in diabetes, severe osteoporosis or cardiovascular disease. However, adju-
vant agents have a corticosteroid-sparing effect and their use in the elderly is limited because
of adverse events, which are more frequent in this population. Associated treatment of
comorbidities can interact with adjuvant drugs and facilitated the involvement of adverse events.
4.2.1. Tetracycline
Tetracycline is recommended as a first adjuvant agent with anti-inflammatory activity confirmed
by reduction of collagenolytic activity [86]. Several small series documented good efficacy and
safety profiles of tetracycline and nicotinamide to treat mild to severe bullous pemphigoid [86,
87]. The therapy regimen is almost always combined with topical high potency corticosteroids.
One randomized controlled study compared doxycycline (200 mg/day) and prednisolone
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(0.5 mg/kg/day) for initial therapy in 256 patients with bullous pemphigoid. Therapy with
doxycycline was evaluated as a useful alternative to prednisolone [88]. The recommended
regimen is oxytetracycline 2 g/day and doxycycline 200 mg/day, both orally. Tetracycline can be
used alone or in combination with nicotinamide up to 2 g/day orally. Nicotinamide, the amide
derivate of vitamin B has been referred to having several types of anti-inflammatory activity,
including inhibition of proinflammatory cytokines [87]. The combination of both may result in
ameliorating of anti-inflammatory activity of bullous pemphigoid. The presence of circulating
autoantibody after clearance of skin lesions is probably based on anti-inflammatory properties
and not on decline of autoantibody production against the basement membrane zone. Tetracy-
cline is regarded as a second-line therapy in pemphigoid diseases.
4.2.2. First-line adjuvant agents: azathioprine, mycophenolate mofetil, methotrexate, and dapsone
First-line adjuvant agents can be used in the same dose as in pemphigus vulgaris and include
azathioprine, mycophenolate mofetil, methotrexate, and dapsone [22, 89, 90]. However, a daily
dose in the lower range is most frequently effective and better tolerated in elderly patients. A
retrospective review evaluated 35 case reports and case series and comprehended data of 170
patients with bullous pemphigoid treated with dapsone alone or combined with corticosteroids.
Clinical remission was achieved in 81% of patients. Adverse events were developed in 37% of
patients and in 5% of patients required discontinuation of dapsone. The most frequent adverse
event was hemolysis and concomitant anemia, both were dose-dependent and reversible [41]. A
small series study compared the efficacy and safety of azathioprine and dapsone in 15 patients
with bullous pemphigoid. Both drugs were effective and showed an acceptable safety profile
[91]. Another small series study compared the corticosteroid-sparing effect of azathioprine and
dapsone in 8 patients with bullous pemphigoid. The corticosteroid-sparing effect was moder-
ately higher in dapsone [92]. A retrospective review evaluated 6 studies comprehending data of
79 patients with bullous pemphigoid treated with methotrexate. Clinical improvement was
achieved in 94% of patients [34]. Another small series study evaluated 16 patients with bullous
pemphigoid treated with methotrexate combined with prednisone. Eight of 16 patients achieved
remission off therapy after 25.3 months and during the 5.5 years of follow-up [93]. A retrospec-
tive study evaluated data of 70 patients with bullous pemphigoid treated with low-dose meth-
otrexate (5–15 mg/week) combined with short-term high potent topical corticosteroid (clobetasol
propionate). The regimen demonstrated very good efficacy and induced clinical improvement in
all patients in a mean time interval of 21.9 days. Long-term disease control was achieved in 76%
of patients [94]. Cyclophosphamide is a very effective immunosuppressant, but also toxic agent,
and so its use in bullous pemphigoid is limited and not generally recommended.
4.2.3. Second-line adjuvant agents: intravenous immunoglobulin G, rituximab, immunoadsorption
Second-line adjuvant agents are used in severe or refractory bullous pemphigoid nonresponsive
to corticosteroids or adjuvants of the first line. They must be used with extreme precaution in
respect of adverse events. Second-line adjuvant medications are the same as in pemphigus and
are utilized by standard rule. However, the number of patients treated with this modality is
much lower compared with pemphigus. The efficacy and safety of second-line adjuvants were
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referred to in several small series and case reports [89, 90]. One review study evaluated 7 clinical
studies and comprehended data of 69 patients with bullous pemphigoid treated with intrave-
nous immunoglobulin. All of the patients showed clinical remission within 14–27 months of
post-intravenous immunoglobulin follow-up. In 10 patients, the titer of both anti-BP180 IgG and
anti-BP230 IgG autoantibodies showed a gradual decline and non-detectable titer after 11months
and 10 months, respectively. No serious adverse event was documented in all patients treated
with intravenous immunoglobulin [57]. Another review study summarized 16 patients with
bullous pemphigoid treated with rituximab; among them 14 patients were treated according to
the lymphoma protocol and 2 patients according to the rheumatoid arthritis protocol. Complete
clinical remission was achieved in 69% of patients and 6% of patients did not show any response.
The mortality rate was 19%. Two patients died from sepsis and one from cardiac event [95]. The
combination of intravenous immunoglobulin and rituximab showed good efficacy and no seri-
ous adverse events in 12 patients with severe and refractory bullous pemphigoid, who did not
respond to previous conventional immunosuppressive therapy. Complete clinical improvement
was achieved in a mean of 4.6 months and previous immunosuppressive therapy was
discontinued. Clinical improvement was correlated with rapid decline of anti-BP180 IgG and
anti-BP230 IgG autoantibodies and thereafter remained undetected. The therapy regimen was
well tolerated without adverse events, including infections. Ten patients remained in remission
in the follow-up at 73.8 months [96]. This regimen could be recommended, if conventional
therapy fails. Patients with bullous pemphigoid and elevated level of IgE and eosinophilia who
do not respond to conventional therapy regimen could be treated with omalizumab, monoclonal
antibody that binds to and declines IgE. It is expected that the anti-BP180 IgE autoantibody
could be pathogenic in some individuals [97].
Immunoadsorption can be used in severe refractory autoimmune bullous diseases has shown
utilization in bullous pemphigoid not responsive to conventional treatment. Only small case
series, or several patients were included into a group of pemphigus patients treated with
immunoadsorption. Respectable patients for this regimen are those with markedly elevated
levels of pathogenic autoantibodies. Clinical improvement is associated with rapid decline of
anti-BP180 IgG and anti-BP230 IgG autoantibodies [67, 68, 70, 98]. Depending on the disease
outcome, immunoadsorption can be used in several cycles. Adverse events do not differ from
those in pemphigus patients and the incidence is low. One case series study documented good
efficacy and safety of immunoadsorption combined with rituximab in various severe and
refractory autoimmune bullous diseases, including bullous pemphigoid (3 patients), mucous
membrane pemphigoid (3 patients), and epidermolysis bullosa acquisita (1 patients). Concom-
itant medication with systemic corticosteroids and other immunosuppressive drugs was
administered. The clinical improvement was compounded with persistent decrease in both
anti-BP180 IgG and anti-BP230 IgG autoantibodies. Complete remission was achieved in all
patients and, in one patient, all immunosuppressive therapy was interrupted. Combined
therapy proved rapid with long-lasting response, and was well tolerated and produced a
corticosteroid-sparing effect [71]. Immunoadsorption is a second-line adjuvant treatment in
autoimmune bullous disease including bullous pemphigoid, mucous membrane pemphigoid
and epidermolysis bullosa acquisita. These second-line adjuvant agents are regarded as a
third-line therapy in pemphigoid diseases.
Current Therapy in Autoimmune Bullous Diseases
http://dx.doi.org/10.5772/intechopen.71541
195
4.3. Therapy of pemphigoid gestationis
Treatment of pemphigoid gestationis is influenced by pregnancy and should be secure to the
fetus. In general, treatment is based on clinical experience. Disorder is almost always self-
limiting, but can be associated with post-partum relapse. The goal of the therapy is to reduce
pruritus and block the production of autoantibodies. Topical high-potency corticosteroids are
the first-line therapy. Usually, topical corticosteroids are combined with systemic antihistamine
which is respectable in pregnancy, e.g., chlorpheniramine or cetirizine. If the topical corticoste-
roid is ineffective, a systemic corticosteroid at a low-mild dose is recommended, e.g., prednis-
olone up to 0.25 mg/kg/day, as an initial dose with subsequent reduction based on clinical
outcome [90, 99]. Severe cases require a high dose of 0.5–1 mg/kg/day of prednisolone [100].
Small and moderate doses of systemic corticosteroid do not affect pregnancy and the fetus,
whereas placental enzyme inactivates 88% of prednisolone [101]. The initial dose should
continue for 1–2 weeks after disease control is reached, then gradually tapered to an adequate
maintenance dose. Alternate day therapy is preferred [102]. Discontinuation of prednisolone
therapy depends on the clinical outcome and can be realized after or before delivery. In
addition, prednisolone is excreted in breast milk in small amount. A dose up to 40 mg/day is
regarded as safe [101]. Severe disease can be treated with intravenous immunoglobulin in a
conventional dose. The safety profiles of intravenous immunoglobulin in pregnant women
were confirmed by several clinical studies in pregnant women with pemphigus [38, 62].
Another choice of treating severe disease and unresponsive disease to conventional treatment
is immunoadsorption [70]. One case report referred to a pregnant patient with severe
pemphigoid gestationis who was successfully treated with immunoadsorption followed by
systemic corticosteroids. After three procedures, disease control was achieved and pathogenic
autoantibodies declined by 89% [103]. Immunoadsorption was evaluated as an effective and
safe treatment modality in pemphigoid gestationis.
4.3.1. Therapy of linear IgA dermatosis
IgA dermatosis is a rare diagnosis that can affect adults, especially women of fertile age and
children. Treatment should be started with topical high-potency corticosteroids. If topical
therapy is ineffective, a systemic corticosteroid should be started, e.g., prednisolone in a dose
of 0.25–0.5 mg/kg/day. In severe cases, when corticosteroids do not achieve disease control,
prednisolone should be combined with dapsone 1 mg/kg/day. It is recommended to initiate the
treatment with dapsone 0.5 mg/kg/day to avoid adverse effects, e.g., hemolytic anemia.
According to the clinical outcome, initial therapy can be enhanced up to a conventional dose
of 100 mg/day or up to ≤1.5 mg/kg/day. In children, dapsone 0.5–2 mg/kg/day is utilized [89].
Another treatment option is tetracycline (2 g/day) combined with nicotinamide (1.5–2 g/day)
[104]. A gluten-free diet is ineffective.
4.3.2. Therapy of mucous membrane pemphigoid (cicatricial pemphigoid)
Treatment of mucous membrane pemphigoid is usually very difficult because of the sequela
that may result in blindness and esophageal stricture despite utilization of immunosuppres-
sive medications. The therapy regimen is based on whether ocular mucosa is afflicted or not.
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Mucous membrane pemphigoid without ocular involvement requires systemic corticosteroids,
e.g., prednisolone over 1 mg/kg/day combined with first-line adjuvant agents like dapsone,
azathioprine or mycophenolate mofetil [105]. All immunosuppressive agents are used in
conventional doses. The preferred medication in mild disease is dapsone being effective in
30–70% of patients. Response to dapsone can be expected within 2–12 weeks [89]. Mucous
membrane pemphigoid with ocular involvement has more severe outcome of disease. In mild-
to-moderate ocular mucous membrane pemphigoid, dapsone is recommended at a dose of
50 mg/day up to a maximum dose of 200 mg/day. Another choice, especially if dapsone cannot
be used, is to utilize sulfapyridine (500 mg/day or two times daily), or sulfasalazine (1–4 g/
day). The anti-inflammatory activity of the last three medications is used in the therapy
regimen [106]. A retrospective study of 23 patients with mucous membrane pemphigoid with
ocular involvement referred to the good efficacy of mycophenolate mofetil. Control of con-
junctival inflammation was achieved in 69.6% of patients within 6 months and in 82.6% of
patients within 12 months of therapy [107]. In patients with ocular involvement, another
choice is a low dose methotrexate. A retrospective clinical study of 17 patients with mucous
membrane pemphigoid demonstrated an improvement in ocular inflammation in 72% of
afflicted eyes and improvement of visual acuity in 85% of eyes [108]. Progressive disease in
ocular involvement requires a more aggressive therapy regimen. Systemic corticosteroid
(prednisolone 1 mg/kg/day) with second-line adjuvant agent, like cyclophosphamide (1–
2 mg/kg/d), is recommended. A retrospective study of 94 patients documented the good
efficacy of cyclophosphamide combined with prednisolone, resulting in total remission of
conjunctival inflammation in 82.9% of patients within 1 year [109]. Recently, new strategies
have been employed to treat a severe refractory disease. Small series documented the good
efficacy and tolerability of intravenous immunoglobulin. Ten patients with progressive ocular
involvement in mucous membrane pemphigoid who were unresponsive to conventional
immunosuppressive therapy reported good efficacy and tolerability of intravenous immuno-
globulin after receiving 4–12 cycles. Clinical improvement and stabilization of ocular disease
was achieved in all patients [110]. Another choice is rituximab. One retrospective study
documented the efficacy of rituximab to 61 eyes of 32 patients with ocular involvement in
mucous membrane pemphigoid. Twenty-six patients achieved clinical remission with an
absence of progressive ocular scarring and ocular inflammation within ≥2 months (average
remission of 24.5 months). The therapy regimen of rituximab was used as a monotherapy (6
patients) or in combination (6 patients), rituximab combined with intravenous immunoglobu-
lin (14 patients) and rituximab combined with intravenous immunoglobulin and other immu-
nosuppressive adjuvant (6 patients). The progression of ocular involvement was controlled
and no cicatrization developed in the follow-up. Adverse effects were mild and transient [111].
4.3.3. Therapy of epidermolysis bullosa acquisita
It is very difficult to treat epidermolysis bullosa acquisita, especially the classic mechano-
bullous form associated with high skin fragility at trauma-prone areas. This form is associated
with dystrophic changes, digital contracture and esophageal stricture. Inflammatory epider-
molysis bullosa acquisita resembles other autoimmune bullous diseases with responses to
anti-inflammatory and immunosuppressive medications. The main stay therapy is systemic
Current Therapy in Autoimmune Bullous Diseases
http://dx.doi.org/10.5772/intechopen.71541
197
corticosteroids, prednisolone 1–1.5 mg/kg/day. Adjuvant agents with corticosteroid-sparing
effect used to treat other autoimmune bullous disease are also effective in the management of
epidermolysis bullosa acquisita. Such adjuvants include azathioprine (1–2 mg/kg/day),
mycophenolate mofetil (1–2 g/day), methotrexate (7.5 mg/week), and cyclophosphamide
(500 mg /day in mode of pulse therapy). In small series, anti-inflammatory drugs including
dapsone (25–100 mg/day) and colchicine (0.6–1.2 mg/day) induced remission [112]. Colchicine
can be used as a single or combined with systemic corticosteroid or dapsone. Adverse events
of colchicine include diarrhea, and renal or hepatic toxicity [113]. One retrospective study of 30
patients with epidermolysis bullosa acquisita referred to the time remission of combined
methylprednisolone with mycophenolate mofetil or cyclophosphamide or azathioprine. One
year after initiation therapy, complete remission was achieved in 33.3% of patients and partial
remission in 32.8% [114]. In severe and refractory cases unresponsive to conventional therapy
regimen, intravenous immunoglobulin, rituximab, plasmapheresis, and immunoadsorption
could be utilized in conventional doses for autoimmune bullous diseases. All of the therapy
modalities were used and documented only in small series of patients with epidermolysis
bullosa acquisita, almost always with good efficacy and total or partial remission. In all
regimens, a good safety profile was documented. Adverse events did not differ from adverse
events in other autoimmune bullous disease [115]. Rituximab combined with intravenous
immunoglobulin was referred in 5 patients with refractory epidermolysis bullosa acquisita.
Patients received a high number of intravenous immunoglobulin (10–26) and 1–2 cycles of
rituximab and achieved adequate improvement of disease, while being well tolerated [116].
The education of patients in the management of topical therapy and preventive measures
against common trauma are obligatory.
5. Therapy of dermatitis herpetiformis
The mainstay therapy in dermatitis herpetiformis is a gluten-free diet that ameliorates both
skin disease and gluten sensitive enteropathy. Precise maintenance of a gluten-free diet of 2
years cleans the skin disease and heals enteropathy. Adherence to a gluten-free diet should be
provided for the whole life. After many years, IgA-antibody deposits disappear from the
dermo-epidermal junction in both bowel and skin [6]. The reintroduction of gluten to the diet
evokes the recurrence of gluten sensitive enteropathy and cutaneous rash within 12 weeks,
frequently sooner. Good adherence to a gluten-free diet within 5–10 years induces improve-
ment of enteropathy and is regarded to have a protective property against lymphoma, which
might be associated with dermatitis herpetiformis [117]. Patients on a gluten-free diet must
exclude cereals containing gluten and its toxic fractions, including wheat, rye, and barley.
Based on some authors, oats can be incorporated into a gluten-free diet, whereas the majority
of patients with dermatitis herpetiformis and gluten-sensitive enteropathy can tolerate moder-
ate amounts of pure oats [118, 119]. Furthermore, oats increase the nutrition value of a gluten-
free diet. Some studies reported that pure oats do not induce systemic or mucosal anti-
body response in patients with coeliac disease [119, 120]. However, oats can be contaminated
with prolamines from other cereals and pure oats are difficult to prepare. This issue requires
further investigation and new agricultural processing and manufacture of oats. Long-term
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administration of a gluten-free diet could permit the discontinuation of systemic medication,
meaning self-sustaining treatment in dermatitis herpetiformis.
The mainstay medication in dermatitis herpetiformis is dapsone at a dose of 50–150 mg/day.
Dapsone usually has a rapid and dramatic effect in suppressing skin symptoms within a few
days, but does not have a curable effect on the underlying enteropathy. The effectiveness of
dapsone has not been confirmed by clinical studies. Multiple and long-lasting empirical utili-
zation of dapsone in practice confirmed its efficacy and safety in dermatitis herpetiformis.
Another choice to treat dermatitis herpetiformis is sulfonamides, when dapsone fails to control
the disease or is not tolerated. Three sulfonamides may be an alternative to dapsone:
sulfapyridine (1.5 g/day), sulfamethoxypyridazine (0.25–1.5 g/day), and sulfasalazine (1–2 g/
day) [6]. Several case reports referred to an alternative treatment using sulfasalazine, which is
commonly utilized in the long-term management of inflammatory bowel disease and as a
second-line agent in rheumatoid arthritis and psoriatic arthritis [121]. All three sulfonamides
may cause the same adverse events, including hypersensitivity reactions and bone marrow
toxicity, resulting in agranulocytosis, aplastic anemia, and methemoglobinemia. More com-
mon and not severe adverse effects are nausea, anorexia, and vomiting. Gastro-enteric events
could be avoided with administration of an enteric-coated form of medication.
Systemic corticosteroids are not recommended for treating dermatitis herpetiformis, because
they are not effective. On the other hand, topical corticosteroids, especially of high potency
(e.g., clobetasol propionate) may reduce itching. Another choice to ameliorate pruritus is third-
generation antihistamine with specific activity on eosinophil activity.
6. Local therapy in autoimmune bullous diseases
In autoimmune bullous disease, the local therapy is important to prevent infection, to control
reepithelization of denuded areas, and to ameliorate pain. Management of bullae depends on
their size. Small bullae stay intact and large bullae should be punctured, but the covering
should stay at the site of previous bullae. The released roof of blister built up a protective
covering that shield the denuded area from secondary infection as well as loss of serum
contents. In extensive disease, bathing with antiseptic agent should be applied, e.g., potassium
permanganate (1:10,000), chlorhexidine or other commercial agent. Denuded areas should be
covered with antiseptic or antibiotic agent in the form of lotions, sprays or cream. A potent
topical corticosteroid, e.g., 0.05% clobetasone propionate cream, is preferably used in bullous
pemphigoid and can be the self-sustaining therapy in mild bullous pemphigoid [82]. The
advantage of topical corticosteroids is their local anti-inflammatory and immunosuppressive
activity, which may be helpful in dropping of the systemic corticosteroid. Topical corticoste-
roids are also successfully utilized to treat minor forms of pemphigus or in the maintenance
phase of therapy management [122]. One clinical study demonstrated the good efficacy of
clometasone propionate 0.05% cream applied to afflicted areas on skin and mucosa in 7
patients with pemphigus vulgaris and pemphigus foliaceus. Topical corticosteroid was used
as self-sustaining therapy. Another topical corticosteroid, betamethasone valerate 0.1% cream,
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was applied to the face. The creams were used twice daily for at least 15 days, up to remission.
Moreover, when clinical improvement was achieved, topical creams were applied in tapering
mode to the area of previous lesions. In 4 patients, relapses occurred when topical treatment
was discontinued, but were successfully controlled by reapplication of topical corticosteroid.
In 3 patients, topical therapy failed, and a systemic corticosteroid was utilized and combined
with other adjuvant agents (dapsone or methotrexate). Topical treatment did not influence
anti-Dsg IgG autoantibody titer. No serious side effect was noticed [123]. Topical corticoste-
roids seem to have only postponed activity in autoimmune bullous disease, because they do
not influence the production of pathogenic autoantibody and utilize only anti-inflammatory
activity. However, topical corticosteroids may help bypass the period before the systemic
immunosuppressive drug should be used to control disease. In addition, minor disease can
be controlled by self-sustained topical corticosteroid. Moreover, the monitoring of pathogenic
autoantibody may indicate a relative threat of relapse and utilization of systemic medication.
In mild disease, a combination of topical corticosteroid with systemic immunosuppressive
agent may induce improvement of clinical outcome. In addition, topical corticosteroids may
support the systemic agent and advocate healing through their local anti-inflammatory activ-
ity. A topical corticosteroid agent can be combined with antibiotic, e.g., gentamycin having
dual activity, anti-inflammatory, and antibacterial.
The therapeutic challenge is the pathologic lesions in mucosa, especially in the oral cavity. The
response to conventional therapy in oral mucosa occurs in a special environment resulting in
delayed healing compared with skin lesions. Topical administration in mucosa should be
modified because the saliva dilutes and shortens the therapeutic activity of medication. There-
fore, corticosteroid should be implicated into an adhesive paste, which allows longer persis-
tence and activity of the medication. Fluocinonide 0.05%, clobetasol 0.05%, and halobetasol
0.05% ointments compounded 1:1 with Orabase have shown good efficacy in oral manage-
ment in 12 patients with oral pemphigus vulgaris. The only adverse effect was candida
infection in the oral cavity, which afflicted most of the patients [124].
Another option in topical management of the oral cavity is triamcinolone acetonide, a high
potency corticosteroid administered perilesional or intralesional to treat recalcitrant and rem-
nant lesions. One clinical study compared perilesional or intralesional triamcinolone acetonide
application and topical cream of 0.1% in 35 patients with recalcitrant oropharyngeal pemphi-
gus vulgaris. Perilesional or intralesional triamcinolone displayed a better clinical outcome
than topical application and induced complete clinical remission, while reducing the total
amount of corticosteroids [125]. A perilesional or intralesional corticosteroid is recommended
only in the maintenance phase of therapy, when 4–6 oropharyngeal sites are involved and do
not respond to conventional immunosuppressive therapy. In addition, immediate use can be
recommended to treat new lesions appearing in the maintenance phase. This regimen is not
recommended upon relapse of disease, because the first step is to enhance systemic immuno-
suppressive medication. Good and meticulous personal oral hygiene and periodic professional
oral hygiene sessions are advisable. Topical antiseptic mouthwash solution containing anes-
thetic agent is useful. However, afflicted mucosa especially that of the oral cavity, shows a
refractory clinical outcome and slow response to systemic therapy. Perilesional or intralesional
triamcinolone acetonide may improve vegetative tissue formation, especially in intertriginous
location in pemphigus vegetans [126].
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The topical immunomodulatory agents, calcineurin inhibitors, are new choice in local manage-
ment of autoimmune bullous disease that promote healing and may enhance reepithelization.
A double-blind, placebo-controlled clinical study referred to the good efficacy and safety
profile of pimecrolimus 1% cream for cutaneous lesions in 11 patients with pemphigus
vulgaris [127]. Another new topical agent, epidermal growth factor (10 μg in cream) was
evaluated in a double-blind, randomized, controlled clinical trial and showed accelerating
efficacy and a good safety profile in 20 patients with cutaneous lesions of pemphigus vulgaris
[128]. Nicotinamide gel 4%, an adjunctive topical gel, was referred as an effective new treat-
ment modality for cutaneous lesions of pemphigus vulgaris in 8 patients in a double-blind,
placebo-controlled study [129]. All new topical medications should be confirmed in large
clinical studies and eventually in practice.
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